Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity. Nurix had initially launched NX-2127 […]